Cargando…

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study

BACKGROUND: Elevated risk of HIV-1 infection among recipients of an adenovirus serotype 5 (Ad5)-vectored HIV-1 vaccine was previously reported in the Step HIV-1 vaccine efficacy trial. We assessed pre-infection cellular immune responses measured at 4 weeks after the second vaccination to determine t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yunda, Duerr, Ann, Frahm, Nicole, Zhang, Lily, Moodie, Zoe, De Rosa, Steve, McElrath, M. Juliana, Gilbert, Peter B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219669/ https://www.ncbi.nlm.nih.gov/pubmed/25369172 http://dx.doi.org/10.1371/journal.pone.0108631

Ejemplares similares

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials
por: Fiore-Gartland, Andrew, et al.
Publicado: (2016)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1
por: Hertz, Tomer, et al.
Publicado: (2013)

MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load
por: Janes, Holly, et al.
Publicado: (2012)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women
por: Musey, Luwy, et al.
Publicado: (1997)

Dynamics of Viral Evolution and CTL Responses in HIV-1 Infection
por: Liu, Yi, et al.
Publicado: (2011)

Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles
por: Migueles, Stephen A., et al.
Publicado: (2011)

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
por: Janes, Holly, et al.
Publicado: (2015)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
por: Seaton, Kelly E., et al.
Publicado: (2021)

The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis
por: Roff, Shannon R., et al.
Publicado: (2014)

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial
por: Fellay, J, et al.
Publicado: (2009)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

P19-48. Induction of Ad5 neutralizing antibodies in placebo recipients during the Step Trial is not associated with risk of HIV infection
por: Spies, G, et al.
Publicado: (2009)

0A07-01. HIV-specific CD8(+ )T-cells of vaccinees exhibit proliferative and cytotoxic capacities comparable to those of progressors
por: Rood, JE, et al.
Publicado: (2009)

CXCR3 enables recruitment and site-specific bystander activation of memory CD8(+) T cells
por: Maurice, Nicholas J., et al.
Publicado: (2019)

Cell free HIV-1 virus can infect inner and outer foreskin polarized explants
por: Lemos, MP, et al.
Publicado: (2012)

Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency
por: Gornalusse, Germán Gustavo, et al.
Publicado: (2021)

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
por: Andersen-Nissen, Erica, et al.
Publicado: (2021)

Preexisting memory CD4(+) T cells contribute to the primary response in an HIV-1 vaccine trial
por: Campion, Suzanne L., et al.
Publicado: (2021)

Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step trial
por: Rolland, Morgane, et al.
Publicado: (2011)

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans
por: Zhao, Lue Ping, et al.
Publicado: (2020)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses
por: Hancock, Gemma, et al.
Publicado: (2015)

HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities
por: Seaton, Kelly E., et al.
Publicado: (2014)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Comparison of Cytotoxic activity and Interferon-g secretion by Natural Killer Cells in HIV-1 and HIV-2 infected individuals
por: Nuvor, Samuel Victor, et al.
Publicado: (2010)

Constitutively Active MAVS Inhibits HIV-1 Replication via Type I Interferon Secretion and Induction of HIV-1 Restriction Factors
por: Gupta, Sachin, et al.
Publicado: (2016)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

Plasmacytoid Dendritic Cells Accumulate and Secrete Interferon Alpha in Lymph Nodes of HIV-1 Patients
por: Lehmann, Clara, et al.
Publicado: (2010)

Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH
por: van Duijn, Janine, et al.
Publicado: (2023)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy
por: Morris, Lynn, et al.
Publicado: (1998)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nlljhgrhn901b8ec4nsmn0evt9